Phase 1 Relapsed Neuroblastoma Clinical Trials

9 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1Phase 2

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Refractory NeuroblastomaRelapsed Neuroblastoma
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 1Phase 2

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Relapsed Neuroblastoma
University of Birmingham160 enrolled23 locationsNCT07334301
Recruiting
Phase 1

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Refractory NeuroblastomaRelapsed Neuroblastoma
Stephan Grupp MD PhD38 enrolled1 locationNCT07007117
Recruiting
Phase 1Phase 2

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Refractory NeuroblastomaRelapsed Neuroblastoma
Roberto Chiarle42 enrolled2 locationsNCT06803875
Recruiting
Phase 1

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Refractory NeuroblastomaRelapsed Neuroblastoma
Stephan Grupp MD PhD45 enrolled1 locationNCT05650749
Recruiting
Phase 1

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

NeuroblastomaRefractory OsteosarcomaRefractory Neuroblastoma+2 more
Emory University24 enrolled1 locationNCT05400603
Recruiting
Phase 1

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Steven DuBois, MD18 enrolled2 locationsNCT07027748
Recruiting
Phase 1Phase 2

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Refractory NeuroblastomaRelapsed Neuroblastoma
Nationwide Children's Hospital31 enrolled1 locationNCT04211675